Waleed Khalid Seddiq

Mr. Waleed Khalid Seddiq

Clinical investigation, Harvard Medical School, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2022 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
JAJoud Mohammed Alkhalifah
Joud Mohammed Alkhalifah
WSWaleed Khalid Seddiq
Waleed Khalid Seddiq
BABadr Fadhel Alshehri
Badr Fadhel Alshehri
AAAlhanouf Hani Alhaluli
Alhanouf Hani Alhaluli
MAMohammed Mesfer Alessa
Mohammed Mesfer Alessa
NANaif Mansour Alsulais
Naif Mansour Alsulais
A comprehensive literature review of Research engines was conducted up to March 2022 to retrieve the articles. We considered all published data, press briefings, and announcements by the Ministry of Health of Saudi Arabia (MOH). The search included both sources in English and Arabic. Thus, this paper aims to give a comprehensive overview of the evolution and role of telemedicine and E-health represented in multiple informatics mobile applications during the COVID-19 pandemic in Saudi Arabia. As a component of its subjective drives, the MOH has launched and developed a total of 12 mobile applications from 2012 to 2019, three apps of which were developed during the COVID-19 pandemic. My health “Sehhaty” was the cornerstone of telemedicine services provided by the MOH in Saudi Arabia during the COVID-19 pandemic. Virtually booked physician appointments exceeded 3.8 million. Appointment “Mawid” app number of users sprinted from 4 million to 25 million users and the number of appointments booked in the same app went from 8 million to 100 million appointments in pre-COVID-19 compared to the post-COVID-19 period. Furthermore, the Health 937 hotline numbers grew to 24.6 million calls. The Health “Seha” app provided 2 million remote medical consultations with an almost 8-fold increase compared to pre-COVID-19 times.

31 May 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
NKNobuhiko Kanaya
Nobuhiko Kanaya
YKYohei Kitamura
Yohei Kitamura
MVMaria Lopez Vazquez
Maria Lopez Vazquez
AFArnaldo Franco
Arnaldo Franco
KCKok-Siong Chen
Kok-Siong Chen
KSKhalid Shah
Khalid Shah
Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first established PTEN-deficient melanoma brain metastasis mouse models and characterized them to be more immunosuppressive compared with primary melanoma, mimicking the clinical settings. Next, we developed an allogeneic twin stem cell (TSC) system composed of two tumor-targeting stem cell (SC) populations. One SC was loaded with oncolytic herpes simplex virus (oHSV), and the other SC was CRISPR-Cas9 gene-edited to knock out nectin 1 (N1) receptor (N1 KO ) to acquire resistance to oHSV and release immunomodulators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF). Using mouse models of brain metastatic BRAF V600E /PTEN −/− and BRAF V600E/wt /PTEN −/− mutant melanomas, we show that locoregional delivery of TSCs releasing oHSV and GM-CSF (TSC-G) activated dendritic cell– and T cell–mediated immune responses. In addition, our strategy exhibited greater therapeutic efficacy when compared with the existing oncolytic viral therapeutic approaches. Moreover, the TSCs composed of SC-oHSV and SC N1KO –releasing GM-CSF and single-chain variable fragment anti–PD-1 (TSC-G/P) had therapeutic efficacy in both syngeneic and patient-derived humanized mouse models of leptomeningeal metastasis. Our findings provide a promising allogeneic SC-based immunotherapeutic strategy against melanomas in the CNS and a road map toward clinical translation.

26 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
JAJoud Alkhalifah
Joud Alkhalifah
WSWaleed Khalid Seddiq
Waleed Khalid Seddiq
MAMohammed Abdullah Alshehri
Mohammed Abdullah Alshehri
AAAbdulkarim Alhetheel
Abdulkarim Alhetheel
AAAhmed Albarrag
Ahmed Albarrag
Mazin BarryMazin Barry
Mazin Barry
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a considerable threat to public health and global economies. SARS-CoV-2 has largely affected a vast world population and was declared a COVID-19 pandemic outbreak, with a substantial surge of SARS-CoV-2 infection affecting all aspects of the virus’ natural course of infection and immunity. The cross-reactivity between the different coronaviruses is still a knowledge gap in the understanding of the SARS-CoV-2 virus. This study aimed to investigate the impact of MERS-CoV and SARS-CoV-2 viral infections on immunoglobulin-IgG cross-reactivity. Our retrospective cohort study hypothesized the possible reactivation of immunity in individuals with a history of infection to Middle East Respiratory Syndrome coronavirus (MERS-CoV) when infected with SARS-CoV-2. The total number of participants included was 34; among them, 22 (64.7%) were males, and 12 (35.29%) were females. The mean age of the participants was 40.3 ± 12.9 years. This study compared immunoglobulin (IgG) levels against SARS-CoV-2 and MERS-CoV across various groups with various histories of infection. The results showed that a reactive borderline IgG against both MERS-CoV and SARS-CoV-2 in participants with past infection to both viruses was 40% compared with 37.5% among those with past infection with MERS-CoV alone. Our study results establish that individuals infected with both SARS-CoV-2 and MERS-CoV showed higher MERS-CoV IgG levels compared with those of individuals infected previously with MERS-CoV alone and compared with those of individuals in the control. The results further highlight cross-adaptive immunity between MERS-CoV and SARS-CoV. Our study concludes that individuals with previous infections with both MERS-CoV and SARS-CoV-2 showed significantly higher MERS-CoV IgG levels compared with those of individuals infected only with MERS-CoV and compared with those of individuals in the control, suggesting cross-adaptive immunity between MERS-CoV and SARS-CoV.

22 January 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
NKNobuhiko Kanaya
Nobuhiko Kanaya
WSWaleed Khalid Seddiq
Waleed Khalid Seddiq
KCKok-Siong Chen
Kok-Siong Chen
YKYoshinori Kajiwara
Yoshinori Kajiwara
LLLucia Moreno Lama
Lucia Moreno Lama
KSKhalid Shah
Khalid Shah
Background: Immune checkpoint inhibitors have shown clinical benefit in non–small cell lung cancer–derived brain metastasis, but their efficacy in lung-to-leptomeningeal brain metastasis remains poor. Methods: A pair-matched RNA expression dataset of patients with non–small cell lung cancer and brain metastases was analyzed to identify brain metastasis–specific suppressive tumor microenvironment features. Next, we created immune-competent lung-to-leptomeningeal brain metastasis mouse models that mimic clinical lung-to-leptomeningeal brain metastasis. We evaluated the efficacy of intrathecal delivery of allogeneic stem cells engineered to release single-chain variable part of the antigen-binding fragment (scFv) anti–programmed cell death 1 protein (PD-1). To enhance tumor cell killing and subsequent modulation of the immune tumor microenvironment, we explored the therapeutic activity of dual stem cells releasing oncolytic herpes simplex virus (oHSV) and scFvPD-1 and profiled immune and metabolic consequences. Results: RNA sequencing analysis of primary non–small cell lung cancer and brain metastases revealed an immune-suppressive tumor microenvironment with reduced immune cells and increased PD-1–positive T cells in brain metastases. We showed decreased immune cells and increased PD-1–positive T cells in the tumor microenvironment of lung-to-leptomeningeal brain metastases compared with primary non-small cell lung cancer in lung-to-leptomeningeal brain metastasis mouse models. Next, we showed that locoregional intrathecal treatment with stem cells releasing scFvPD-1 but not conventional systemic injection of anti–PD-1 antibodies suppressed tumor growth and improved survival in our immune-competent lung-to-leptomeningeal brain metastasis models. Furthermore, dual–stem cells releasing oHSV and scFvPD-1 enhanced therapeutic outcomes by inducing oHSV–mediated immunogenic cell death, activating antitumor T-cell signaling, and disrupting oxidative phosphorylation, all of which sensitized tumors to cisplatin. Conclusion: Locoregional delivery of dual–stem cells releasing oHSV/scFvPD-1 effectively targets the immune-suppressive tumor microenvironment in lung-to-leptomeningeal brain metastasis, providing a promising strategy for treating lung-to-leptomeningeal brain metastases.

22 February 2024 in Colorectal Disease
Verified
Journal Article
Closed access
GCGustavo Yano Callado
Gustavo Yano Callado
RLRodrigo de Almeida Leite
Rodrigo de Almeida Leite
SASergio Eduardo Alonso Araujo
Sergio Eduardo Alonso Araujo
LBLeandro Cardoso Barchi
Leandro Cardoso Barchi
WSWaleed Khalid Seddiq
Waleed Khalid Seddiq
RRRocco Ricciardi
Rocco Ricciardi